drugset

drugset / Trial / NCT06373406

A Study of MHB036C for Advanced Solid Tumor

NCT06373406 ↗

Phase 1/2 Active not recruiting 200 enrolled Minghui Pharmaceutical (Hangzhou) Ltd

NaSingle-groupOpen-labelTreatment

Summary

Phase I/II, dose escalation and dose expansion study to evaluate the efficacy and safety of MHB036C in advanced malignant tumors.

Timeline

Start: 2023-05-26
Primary completion: 2025-12
Completion: 2026-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MHB036C	Other / unclassified	—	Intravenous

Indications